drug: buprenorphine |
|
*| Clinical class | narcotic analgesic; replacement |
| Action | mu opioid partial agonist; kappa opioid antagonist |
| Chemical class | opioid, thebaine derivative, phenanthrene |
| CSA schedule | III, V |
| DEA number | 9064 |
| Routes of administration | parenteral, sublingual, transdermal |
| Associated with (substance-related)
|
disorders: disorders |
| Availability | prescription |
Also:
- buprenorphine bibliography
- Drug Addiction Treatment Act of 2000
- National Alliance of Advocates for Buprenorphine Treatment
- Physician waiver information
U.S. Preparations:
- Buprel™ (DrugAbuse Sciences) in development
- Buprenex (Reckitt Benckiser) FDA approved indications: relief of moderate to severe pain 12.29.1981
- Norvex™ (Biotek) FDA approved indications: not approved
- Probuphine™ (Titan) in development
- Suboxone® (combination with naloxone)
| Dose: | 2.0 mg. buprenorphine/0.5 mg. naloxone | 8.0/mg. buprenorphine/2.0 mg. naloxone | ||
| Color: | orange | orange | ||
| Shape: | hexagonal | hexagonal | ||
| Type: | tablet | tablet | ||
| Imprint: | sword logo | "N2" | sword logo | "N8" |
- Subutex® (Reckitt Benckiser) FDA approved indications: treatment of opiate dependence 10.8.2002
| Dose: | 2.0 mg. | 8.0 mg. | ||
| Color: | white | white | ||
| Shape: | oval | oval | ||
| Type: | tablet | tablet | ||
| Imprint: | sword logo | "B2" | sword logo | "B8" |
International Preparations:
- Anorfin, Buprex, Burondal, Prefin, Temgesic®
- Temgesic® nX (combination with naloxone)
- Transtec® (Napp)
Street Names:
- bupe
Treatment Guidelines
|
Books and Other
Media: Follow the hypertext link to purchase items. |
|
- Cowan, Alan & Lewis, John W. (Editors) Buprenorphine - Combating Drug Abuse With a Unique Opioid Paperback 1995
- Kings and Queen DVD (2004) Emmanuelle Devos, Mathieu Amalric, Catherine Deneuve
*Molecule graphic courtesy of Steve Chapman